Condition

Doxorubicin Induced Cardiomyopathy

ClinicalTrials.gov condition label

Clinical trials7

Recruiting1

Common interventions12

Lead sponsors shown6

Clinical trials

7 shown

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced CardiotoxicityNCT06427226 · 2024-10-31

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer PatientsNCT07370506 · 2026-02-01

NOT_YET_RECRUITING

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer PatientsNCT06092606 · 2023-04-04

The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer PatientsNCT07668076 · 2022-11-15

99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast CancerNCT02677714 · 2016-11-02

Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via ChemotherapyNCT02796365 · 2016-06-01

Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer PatientsNCT03000036 · 2012-07-01

Common interventions

99mTc-rhAnnexin V-128RADIATION1 Achieva, Philips Medical Systems (3T magnet)DEVICE1 AtorvastatinDRUG1 Control group:DH001 placeboDRUG1 Dapagliflozin 10mg TabDRUG1 DoxorubicinDRUG1 Doxorubicin (DOX)DRUG1 ExerciseOTHER1 Gadoterate MeglumineDRUG1 TelmisartanDRUG1 Trial group: DH001 high-dose groupDRUG1 Trial group: DH001 low-dose groupDRUG1

Leading sponsors

Tanta University2 Advanced Accelerator Applications1 Damanhour University1 Henry Ford Health System1 Monyan Pharmaceutical (Shanghai) Co., Ltd.1 University of Campinas, Brazil1

Trial status mix

COMPLETED3

NOT_YET_RECRUITING1

RECRUITING1

TERMINATED1

UNKNOWN1

Phase mix

PHASE25

NA2

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.